Cargando…
The Biology and Targeting of FLT3 in Pediatric Leukemia
Despite remarkable improvement in treatment outcomes in pediatric leukemia over the past several decades, the prognosis for high-risk groups of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), as well as for relapsed leukemia, remains poor. Intensification of chemotherapy regimen...
Autores principales: | Annesley, Colleen E., Brown, Patrick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172015/ https://www.ncbi.nlm.nih.gov/pubmed/25295230 http://dx.doi.org/10.3389/fonc.2014.00263 |
Ejemplares similares
-
Developments and challenges of FLT3 inhibitors in acute myeloid leukemia
por: Ge, Shuai-Shuai, et al.
Publicado: (2022) -
CPX-351 in FLT3-mutated acute myeloid leukemia
por: Andrews, Claire, et al.
Publicado: (2023) -
FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
por: Kennedy, Vanessa E., et al.
Publicado: (2020) -
The interplay of FLT3 and CXCR4 in acute myeloid leukemia: an ongoing debate
por: Klement, Laura, et al.
Publicado: (2023) -
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia
por: Bruno, Samantha, et al.
Publicado: (2021)